@article {CollazoP6.414作者={虹膜马林Collazo布莱恩Weinshenker和Zahra Nasr阿方索洛佩兹},title ={长期死亡率Neuromyelitis视谱系障碍(P6.414)},体积={90}={15}补充数量,elocation-id = {P6.414} ={2018},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:评估患者的长期结果视Neuromyelitis谱系障碍(NMOSD)。首页背景:Pre-aquaporin-4免疫球蛋白研究报告称,五年生存率68 \ %,平均17.5年(y)的生存。更多的当代研究报告死亡率大约25 \ %的那些疾病持续时间不到10年。非裔美国人的种族与更高的死亡率有关。设计/方法:回顾性研究在梅奥诊所的病人评估开始前10月,2006年。结果:143名患者被确认;22日(15 \ %)死亡,4男性和18个女性;死亡的平均年龄是58.5 y (41 {\ textendash} 94)。已故的比较与患者生活在这个研究显示:跟进中位数为3 y(范围0 {\ textendash} 8)和6 y (0 {\ textendash} 21);疾病持续时间中位数为11个y (3 {\ textendash} 28)和16个y (9 {\ textendash} 49);发病的年龄中位数是43 y (30 83 {\ textendash})对39个y(71年21 {\ textendash});平均数量的复发是6 (2 {\ textendash} 22)和5 (5 {\ textendash} 19);中最后扩大残疾状态量表(eds)得分为7.5 y (4 {\ textendash} 8)和4 (0 {\ textendash} 8); 21 (95\%) received immunotherapy for NMOSD versus 113 (93\%); median time to initiation of treatment was 4y (0{\textendash}21) in those deceased and 5y (0{\textendash}39) in those living. Among the deceased patients, 16 (73\%) were Caucasian, 4 (18\%) African American and 2 (9\%) of unknown ethnicity, whereas among living patients 72 (60\%) Caucasian, 14 (12\%) African American, 11 (9\%) Hispanic, 8 (3\%) Asian, 4 (2\%) Native American, 2 (2\%) Middle Eastern and 9 (7\%) of unknown ethnicity.Conclusions: Patients in this study experienced a lower mortality rate than reported in previous studies. EDSS was identified as a risk factor for mortality.Disclosure: Dr. Marin Collazo has nothing to disclose. Dr. Weinshenker has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis, Alexion, MedImmune, Caladrius Biosciences, Brainstorm Therapeutics. Dr. Nasr has nothing to disclose. Dr. Lopez has nothing to disclose.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/90/15_Supplement/P6.414}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }